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Central Core Disease (CCD) is a congenital myopathy characterized by presence
of amorphous central areas (or cores) lacking glycolytic/oxidative enzymes and
mitochondria in skeletal muscle fibers. Most CCD families are linked to mutations in
ryanodine receptor type-1 (RYR1), the gene encoding for the sarcoplasmic reticulum
(SR) Ca2+ release channel of skeletal muscle. As no treatments are available for
CCD, currently management of patients is essentially based on a physiotherapic
approaches. Functional electrical stimulation (FES) is a technique used to deliver low
energy electrical impulses to artificially stimulate selected skeletal muscle groups. Here
we tested the efficacy of FES in counteracting muscle loss and improve function in
the lower extremities of a 55-year-old female patient which was diagnosed with CCD
at the age of 44. Genetic screening of the RyR1 gene identified a missense mutation
(c.7354C>T) in exon 46 resulting in an amino acid substitution (p.R2452W) and a
duplication (c.12853_12864dup12) in exon 91. The patient was treated with FES for
26 months and subjected before, during, and after training to a series of functional
and structural assessments: measurement of maximum isometric force of leg extensor
muscles, magnetic resonance imaging, a complete set of functional tests to assess
mobility in activities of daily living, and analysis of muscle biopsies by histology and
electron microscopy. All results point to an improvement in muscle structure and function
induced by FES suggesting that this approach could be considered as an additional
supportive measure to maintain/improve muscle function (and possibly reduce muscle
loss) in CCD patients.
Keywords: activities of daily living, congenital myopathy, excitation-contraction coupling, physiotherapy, genetic
screening, ryanodine receptor type-1, training
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INTRODUCTION
Central core disease (CCD), first described in 1956 (1), is one of
the most common human congenital myopathies characterized
by hypotonia and proximal muscle weakness (2). The typical
form of dominantly inherited CCD is usually associated with
a moderate degree of disability and carries an overall favorable
prognosis, although clinical variability is often observed even
within the same family (3–5). Diagnosis of CCD is confirmed by
examination ofmuscle biopsies showing amorphous central areas
(or cores) lacking glycolytic/oxidative enzymes andmitochondria
(6), and disorganization of contractile and sarcotubular systems
(7). Orthopedic complications are frequent in CCD and comprise
congenital dislocation of the hips (8), scoliosis (9), and foot
deformities (10).
About 90% of CCD cases are linked to mutations in the RYR1
gene (11–13), encoding for a tetrameric protein of about 2,200
KDa that forms the sarcoplasmic reticulum (SR) Ca2+ release
channel of skeletal muscle, i.e., the ryanodine receptor type-1
(RyR1). RyR1 is a key protein in excitation-contraction (EC)
coupling, the mechanism that allows the transduction of the
action potential into Ca2+ release from the SR (14, 15).Mutations
in the RYR1 gene are also responsible of malignant hyperthermia
susceptibility (MHS), a hypermetabolic response to commonly
used halogenated/volatile anesthetics (16). Many patients with
CCD test positive for MHS, and, hence, should be considered at
risk during general anesthesia.
No treatment is currently available for CCD and management
of patients is essentially supportive based on a multidisciplinary
approach. Usually, orthopedic complications limit the ability of
CCD adult patient to perform physical exercise (2). Regular
physiotherapy aims to preserve muscle function and to prevent
contractures, particularly those of the achilles tendon, which are
common in CCD. Considering a tendency to exercise-induced
myalgia in CCD, exercises involving a high-resistance load are
not recommendable.
Results collected in mice carrying human mutations linked to
CCD in humans have provided evidence that oxidative stress may
represent a pathophysiological mechanism in CCD and other
RYR1-related myopathies (17). Accordingly, the antioxidant N-
acetylcysteine (NAC) has been proposed to represent a potential
therapy for patients with RYR1 (17, 18). Based on these
experimental evidences and considering that NAC has been
approved by FDA as a drug for various indications, clinical trials
have recently been started to test the efficacy of this treatment
(19, 20).
An independent line of work has led us to consider Functional
Electrical Stimulation (FES) technique as a possible treatment for
CCD patients. FES is a technique that uses low energy electrical
pulses to artificially generate bodymovements. FES was originally
used to develop neuroprostheses that were implemented to
Abbreviations: ADL, activities of daily living; CCD, central core diseases;
EM; electron microscopy; FES, functional electrical stimulation; MIF, maximum
isometric force; MRI, magnetic resonance imaging; RYR1, ryanodine receptor
type-1; SPPB, short physical performance battery; SPWT, self-paced walk test; ST,
stabilometric test; TUGT, timed up and go test.
permanently substitute impaired functions such as grasping,
walking, bladder voiding, and standing in individuals with spinal
cord injury (SCI), head injury, stroke and other neurological
disorders (21–23). FES has been successfully used to rescue
muscle structure and function in animal models (24–26) and to
promote recovery of muscle mass, structure and function in the
lower limb of SCI patients with complete lesion of the conus
cauda (21, 27–29). Recently, we also considered the use of FES
as a method to improve muscle function in elderly, in a study in
which the effects of FES onmuscle was analyzed at the functional,
structural, and molecular level (30).
In the present study, we tested the efficacy of 26months of FES
training in counteracting muscle loss and improving structure
and function in the lower extremities of a 55-year-old female
patient diagnosed with CCD at the age of 44. Measurement
of maximum isometric force (MIF) of leg extensor muscles,
magnetic resonance imaging (MRI), a complete set of functional
tests to assess mobility in activities of daily living (ADL), and
finally the analysis of muscle biopsies by histology electron
microscopy (EM) all point to an improvement of muscle mass,
structure, and function induced by FES.
MATERIALS AND METHODS
Genetic Screening
Mutation screening by conventional Sanger sequencing on
specific regions of the RYR1 gene was performed in all family
members for whom DNA was available (Figure 1). In detail,
primers were designed using Primer3 software (http://frodo.
wi.mit.edu/primer3) to amplify all RYR1 exons (11). Genomic
DNA was extracted from peripheral blood leucocytes by
standard procedures (31, 32). Amplified DNA fragments were
directly sequenced on an ABI3500 Genetic Analyzer (Applied
Biosystems), using the Big-Dye Terminator v3.1 kit and analyzed
with Sequencher 5.0 software (Gene Codes Corporation). DNA
mutation numbering was based on cDNA reference sequence
(NM_000540.2), taking nucleotide +1 as the A of the ATG
translation initiation codon. The mutation nomenclature used
follows that described at http://www.hgvs.org./mutnomen/.
Functional Electrical Stimulation (FES)
Training Protocol
Stimulators and electrodes used in this study derives from devices
developed in the EU project RISE (21, 28). The FES training
procedure was developed by Dr. H. Kern and colleagues and
previously applied on SCI patients with complete lesion of the
conus cauda to promote recovery of muscle mass, structure and
function in the lower limb (27–29, 33). The patient was provided
with stimulators and electrodes at home, and after appropriate
training and instructions, was able to perform stimulation at
home. Two pairs of large electrodes, each having an area of
200 cm2, were strapped to the anterior surface of the thighs
in proximal and distal positions (see Figure S2, for additional
detail). Twitch contractions were elicited by biphasic rectangular
current pulses lasting 100 to 150ms and up to ±200mA
amplitude, representing an impulse energy up to ∼2 Joules, to
recruit fibers throughout the Quadriceps Femoris muscles. The
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FIGURE 1 | Family pedigrees. The black filled symbol represents the affected
proband. Sequence analysis of the proband RYR1 gene identified a missense
mutation (c.7354C>T) in exon 46, resulting in the substitution of an Arg in
position 2452 with a Trp (p.R2452W), and a duplication
c.12853_12864dupACGGCGGCCACG involving 4 amino acid residues (Thr,
Ala, Ala, Thr, p.Thr4285_Thr4288dup) in exon 91. The genotype of family
members tested is reported below each symbol.
long duration of the impulses needed for stimulation precluded
the use of frequencies that would elicit tetanic contractions:
training was initiated at 2Hz, delivered for 15 min/day (series
of 4 s on, 2 s off), 3 days/week. During the first/second month,
muscle excitability progressively increased allowing an increase
of 2Hz stimulation, 2 × 10min stimulation (2min rest). As
training proceeded, excitability of the muscle continued to
increase, and from the third month onwards, training time
stimulation were increased to 3× 10min (2 min rest).
Experimental Design and Assessment of
Effects of FES
Muscle structure and ultra-structure was assessed by Magnetic
Resonance Imaging (MRI), histology, and Electron Microscopy
(EM). Muscle function was assessed by measuring maximum
isometric force (MIF) and stabilometric test (ST), and using a
complete set of functional tests to assess mobility in activities
of daily living (ADL): Timed Up and Go Test (TUGT), 10m
Self Paced Walk Test (SPWT), and Short Physical Performance
Battery (SPPB) as in Kern et al. (30). The effect of FES on
muscle structure and function was assessed by doing all the tests
mentioned above before the beginning of the 26 months of FES
stimulation (T0), and at 3 different time points: T1, 5 months; T2,
14 months; T3, 26 months. See Figure 2 for additional detail.
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging was performed using a Philips
Achieva 1.5 Tesla scanner (Best, The Netherland) using a
quadrature body coil. The patient was comfortably placed in the
supine position. Three axial TSE T2- and SE T1-weighted images
(slice thickness 5mm) were acquired at 3 different muscular
levels: pelvic, thigh and leg. MRI was performed at 3 different
time-points (T1, T2, and T3) after starting the FES training (see
Figure 2). The cross-sectional area of quadriceps and hamstrings
muscles (Figure 3) was estimated using Vue PACS software from
Carestream Health, Inc. (Rochester, NY USA).
MRI was performed with a 1.5 Tesla scanner using a surface
coil. Spin-echo (SE) T1 and Turbo Spin-echo (TSE) T2-weighted
axial images (25 slices; slice thickness 10mm; gap 10mm) were
conducted perpendicular to the long axis of the femur covering
the entire leg from the hip to the knee joint. SE and TSE
sequences were used because of the intrinsic different signal
intensity between fat (hyperintense) and muscle (intermediate)
in both T1 and T2 weighting. The duration time of the image
acquisition was about 9 min: 1′ to obtain reference images; 3′13′′
for SE T1 and 3′30′′ for TSE T2 images. Axial images were then
transferred to a workstation and 2 distinct regions of interest
(ROI) were manually drawn by a radiologist with 5 years of
experience in muscolo-skeletal disease to contour muscle and fat
tissue. ROIs were drawn comparing T1 and T2-weighted images
obtained at 3 different levels: proximal, intermediate and distal
quadriceps. The area of the ROIs was considered to calculate the
fat fraction in each level using the formula: Fat tissue ROIs/Total
muscle ROIs.
Measurements of Maximum Isometric Force (MIF)
Isometric measurements of force produced during leg extension
was assessed using a leg extensor machine (Teca srl; Caldari
Stazione CH, Italy) equipped with a load cell (Globus Italia;
Codognè TV, Italy). Strength of the left and right knee extensors
was measured at T0, T1, T2, and T3 of the study (Figure 4A).
Briefly, the subject was positioned with hip at 90◦ flexion, the
knee at 60◦ flexion (full knee extension = 0) and the arms
crossed at the chest. The shank brace was positioned on the
distal 1/3 of the lower leg and the trunk fixed with a seat belt
tightening system. The subject was instructed to push alternating
with one leg as fast and as hard as possible against a shank
support separated through 1-min rest. In each case the maximal
voluntary contraction was sustained for 3 s. All measurements
were repeated three times for the right and left leg. The best value
of each leg was taken for statistical analyses (34).
Stabilometric Test (ST)
Stability was evaluated using a static force platform (Globus Italia;
Codognè TV, Italy) at T0, T1, T2, and T3 of the study (Figure 4B).
During the assessment of static stability subject stood barefoot in
a natural position, arms at their sides and forefoot open to 30◦
with eyes open facing a target placed 1.5m away and eyes closed.
The ground reaction force vectors were analyzed to calculate
the center of pressure (COP) position (35). To calculate mean
value of the excursions of COP, 3 trials were performed for each
condition, each lasting 51.2 s, in accordance with the guidelines of
the French Posturology Association. The sampling frequency was
120Hz. The key dependent variables of the COP displacement
are: its surface area and its total length, taken as the surface of the
confidence ellipse enclosing 90% of COP sway (36).
Activities of Daily Living (ADL) Tests
A complete set of tests to access mobility in ADL was performed
as in Kern et al. (30) to evaluate the effect of FES at T0, T1, T2,
and T3 of the study (Figure 5):
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FIGURE 2 | Flowchart of measurement procedure. Flowchart of the measurements performed in each period of the study (T0, T1, T2, and T3).
FIGURE 3 | Magnetic Resonance Imaging (MTI) of thigh muscles. MRI was performed after 5 (A; T1), 14 (B; T2), and 26 months (C; T3) of home-based FES. The
cross-sectional area of quadriceps (brown) and hamstrings (green) muscles was estimated and plotted in (D,E), respectively. Histogram in (F) show the variation of fat
fraction (FF) during FES treatment.
(1) Timed-Up-And-Go-Test (TUGT). The subject was asked to
stand up from a standard chair, walk a distance of 3m, turn
around, walk back to the chair and sit down again as fast
as possible. The patient used her usual footwear and no
assistive walking device. Timing, using a stop watch Track
Pro (Conrad Electronics; Hirschau, Germany), begins when
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FIGURE 4 | Maximum Isometric Force (MRI) and Stabilometric Test (ST). (A) Measurements of MIF based on leg extension movement before (T0) and after 5 (T1), 14
(T2), and 26 (T3) months of FES training. (B) Variations in MIF expressed as percentage, where values from T0 were taken as 0%. (C,D) Effect of FES treatment on
surface (mm2) and total length (mm) in ST (52.2 s), in eyes open and eyes closed configuration, before (T0), and after 5 (T1), 14 (T2), and 26 (T3) months of
home-based FES training.
the subject starts to leave the chair back and ends when she
was seated on the chair again (37).
(2) 10m Self Paced Walk Test (SPWT). The patient was asked to
walk a distance of 10m with either: (i) her habitual speed
(i.e., the self-chosen normal speed of walking); or (ii) at
her fastest walking speed. Each task was performed three
times. Parameters of gait (average walking speed, average
step length, and average step cadence) for each 10m walking
trial were calculated using a combination of a standard stop
watch Track Pro (Conrad Electronics; Hirschau, Germany),
counting the number of steps and subjective estimation of
the remained part of the last step as described. The mean
values of the parameters of three trials of each speed were
taken for further analyses (30).
(3) Short-Physical-Performance-Battery (SPPB). The SPPB used
for this study evaluates the lower extremities function by
using tests of gait speed (the fastest time of two 4m walk),
standing balance (side-by-side, semi-tandem, and tandem
stance for 10 s) and the time needed to rise from a chair for
five times as quickest as possible with the arms folded across
their chest. In each test the subject can reach a maximum
score of 4. The sum of the three components comprised
the final SPPB score with a possible range from 0 to 12
points (38).
Muscle Biopsies
Needle muscle biopsies were harvested through a small skin
incision taken from the right Vastus Lateralis (VL) muscle of the
patient at T0 and at T2 of the study. Biopsies were taken using
a semi-automatic needle Precisa 13 Gauge (Hospital Service;
Rome, Italy) as previously described by Franzini-Armstrong and
collaborators (39). All the resulting specimens were then fixed for
either light or Electron Microscopy (EM).
Histological Analysis and Electron Microscopy (EM)
Muscle biopsies were kept for ∼3min at room temperature in a
“K acetate” solution (150mM K acetate, 5mM MgSO4, 10mM
EGTA, 10mM phosphate buffer, pH 7.2) as in Pietrangelo et al.
(39) and were fixed in freshly prepared 3.5% glutaraldehyde in
0.1M cacodylate (NaCaCO) buffer, pH 7.4. The fixed bundles of
fibers were stored at 4◦C, till embedding. Samples were rinsed
in 0.1M NaCaCO buffer and post-fixed for 1 h in a mixture
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FIGURE 5 | Activities of daily living (ADL) tests. Results of ADL tests of before
(T0) and after 5 (T1), 14 (T2), and 26 (T3) months of home-based FES training:
(A) 10m self-paced walk test; (B) TUGT, time up and go test; and (C) SPPB,
short physical performance battery.
containing 2% osmium tetroxide (OsO4) and 0.8% potassium
ferrocyanide [K3Fe(CN)6]. Specimens were then rinsed with
distilled water, rapidly dehydrated in graded ethanol and acetone,
infiltrated with Epon 812-acetone (1:1) mixture, and then
embedded in Epon 812 resin (40).
For EM (Figure 6), ultrathin sections (50 nm) were cut
with a Leica Ultracut R (Leica Microsystem; Vienna, Austria)
using a Ultra Diatome diamond knife (Diatome Ltd.; Biel,
Switzerland) and stained in uranyl acetate and lead citrate
solutions. Sections were examined with a FP 505 Morgagni
Series 268D electron microscope (FEI Company; Brno, Czech
Republic) at 60 kV, equipped with a Megaview III digital camera
and AnalySIS software Olympus Soft Imaging Solutions GmbH
(Munster, Germany).
For histological analysis (Figure 7), semithin sections
(700 nm) were cut with a Leica Ultracut R (Leica Microsystem;
Vienna, Austria) using a Histo Diatome diamond knife (Diatome
Ltd.; Biel, Switzerland) and stained with a 1% Toludine blue O,
1% Sodium Borate Tetra solution in distilled water for 3min on
a hot plate at 55–60◦C. After washing and drying, sections were
mounted with mounting medium DPX Mountant for Histology
(Sigma-Aldrich; Milan, Italy) and observed with a Leica DMLB
light microscope R (Leica Microsystem; Vienna, Austria)
equipped with a Leica DFC 450C digital camera and Leica
Application Suite v4.1.0 (Leica Microsystem; Vienna, Austria).
Fibers were examined for the presence of either contracture or
unstructured cores as in Boncompagni et al. (41).
RESULTS
Case Presentation
The 55-year-old Caucasian woman enrolled in the study was
diagnosed with CCD (CCD; OMIM# 117000) at the age of
44 (Center for Neuromuscular Diseases; Ospedale Clinicizzato
SS. Annunziata, I-66100 Chieti, Italy). CCD was confirmed
by histological examination of muscle biopsies at the time
of the initial diagnosis (not shown). Presence of areas of
internal disarray in skeletal muscle fibers was also confirmed
in the present study (please see Figure S1, for more detail).
The patient reported that her disease had been aggravated by
orthopedic complications (scoliosis diagnosed at the age of 17
years) that limited her daily activities to a point in which
she retired from working activities at the age of 54. At the
time of enrolment in the present study a medical check-up
was performed (anthropometric data, medical aptitude, and
anamnesis): her vital signs were all within normal limits, except
for a moderately high body mass index (Table 1). The score of
muscle strength test by the Medical Research Council scale was
3/5 in both upper and lower limbs (42). Patient had a waddling
gait and difficulty in climbing stairs.
Genetic Screening
Sequence analysis of the RYR1 gene identified a missense
mutation (c.7354C>T) in exon 46 resulting in the substitution
of the Arg in position 2452 with a Trp (p.R2452W) and a
duplication (c.12853_12864dup12, p.Thr4285_Thr4288dup) in
exon 91, involving 4 amino acid residues (Thr, Ala, Ala, Thr,
p.Thr4285_Thr4288dup) in exon 91 was also observed. To
test how these two mutations segregate in the family, DNA
samples from relatives were obtained and analyzed by direct
sequencing (Figure 1). This analysis indicated that mutations are
independently transmitted in the family and that the proband
inherited the c.12853_12864dup12 duplication from the father
and the c.7354C>T mutation from the mother. Analysis of
the daughter and the son of the proband, indicated that both
inherited only the duplication from the father. From a clinical
point, neither the parents nor the sons of the proband presented
signs of myopathy or CCD.
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FIGURE 6 | Appearance of skeletal fibers in electron microscopy (EM). Fibers were classified by EM for the quantitative analysis in different categories: (A) apparently
normal fibers (A) with a typical pale-dark striation; (B) fibers with unstructured cores, presenting extended areas in which myofibrils were disrupted and replaced by
amorphous cytoplasmic material; (C) fibers with contracture cores, with extended regions with laterally-packed and over-contracted myofibrils. Scale bar: 1µm.
Percentage, before (T0) and after 14 months (T2) were respectively reported in column A, B, and C. Data are expressed as % of total fibers analyzed; *p < 0.05 vs. T0.
FIGURE 7 | Histological images from biopsies before (A) and after FES
training (B). Stars and arrows in (A) mark respectively fibers with unstructured
cores and fibers with contracture cores. Empty arrows in (B) points to regions
in which striation is not yet completely rescued. Scale bar: 20µm.
FES Training Protocol
Stimulators and electrodes used in this study derives from devices
developed in the EU project RISE (21, 28). The patient was
provided with stimulators and electrodes, and after appropriate
training and instructions, was able to perform FES at home
(please see Figure S2, for more detail). The effect of FES on
muscle function and structure was assessed by measurement
of maximum isometric force (MIF) of leg extensor muscles,
magnetic resonance imaging of lower extremities (MRI), a
complete set of functional tests to assess mobility in activities
of daily living (ADL) and, finally, histological and electron
microscopy (EM) analysis of muscle biopsies. Functional tests
and structural studies were performed before the beginning of
the 26 weeks of FES stimulation (T0), and at 3 different time
points during FES training: T1 (5 months), T2 (14 months), and
T3 (26 months). See section Materials and Methods and Figure 2
for additional detail about stimulation protocols and adjustment
of parameters during the different phases.
Effects of FES Treatment on Thigh Muscles
as Assessed by MRI
Figures 3A–C shows representative color MRI of thigh muscles
after 5, 14, and 26 months of FES training (T1, T2, and T3,
respectively). Unfortunately, data at T0 were not collected. Data
collected from measurements of MRI scan images are plotted
in Figures 3D–F. The average cross sectional area (CSA) of the
quadriceps (brown in Figures 3A–C) increased of about 15%
from T1 to T2 and of about 18% at T3 (Figure 3D). The size
of quadriceps muscle increased similarly in the right and left
leg, while no changes were detected in the hamstrings muscles,
i.e., the posterior muscles of the thigh (green in Figures 3A–C).
Note that, during stimulation, the surface electrodes were placed
on the front part of the thigh, in correspondence to quadriceps,
and, as a consequence, hamstrings were not directly stimulated by
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TABLE 1 | Anthropometric measurements.
T0 T1 T2 T3
Weight 61.1 65.5 69.3 64.5
Height 145 145 145 145
BMI 29.01 31.15 32.96 30.71
Data reported are the anthropometric measurements of patient during the study, before
(T0) and after 5 (T1), 14 (T2), and 26 (T3) months of home-based FES training.
FES. Figure 3F shows increased percentage of free fat mass at T3.
These results indicate that FES treatment increased muscle mass
at T2 and T3 and reduced fat fraction area at T3. See Table S1 for
additional detail.
Functional Tests
To investigate the beneficial effect of FES treatment on muscle
strength and balance of the patient, maximum isometric force
(MIF) and orthostatic balance during a stabilometric test (ST)
were tested.
Maximum Isometric Force (MIF)
Isometric strength of leg extensor muscles was measured before
(T0), and after 5 (T1), 14 (T2), and 26 (T3) months of
FES treatment (Figures 4A,B). MIF increased in both legs
(Figure 4B), beginning at 5 months (T1, 8%) of treatment and
continuing during the entire length of the study (9% at T2, and
11% at T3).
Stabilometric Test (ST)
Surface area and length of center of pressure (COP) measured
before (T0) and after 5 (T1), 14 (T2), and 26 (T3) months
of FES treatment are shown in Figures 4C,D. In general,
COP displacement in both tested conditions (eyes open and
eyes closed), revealed an important decrease in surface area
(amplitude of oscillatory movements) and in total length
(frequency of oscillatory movements) at T1 that persisted in the
following periods (T2 and T3). These results indicate that the
capability of the patient to maintain balance while standing was
already improved after only 5 months of FES training.
Activities of Daily Living (ADL) Tests
We monitored whether improved muscle force and balance
while standing (Figure 4) was associated with an effective
improvement of the patient’s Activities of Daily Living (ADL).
A complete set of tests to assess mobility of the patient was
employed as in Kern et al. (30) to evaluate the effect of FES
at the different time points of the study: Timed-Up-And-Go-
Test (TUGT), 10m Self Paced Walk Test (SPWT), and Short
Physical Performance Battery (SPPB) (Figure 5). The results of
these tests were slightly contradictory, as at T1 and T2 the results
collected point to a worsening of the patient’s performance, while
a possible improvement was detected at T3: (a) shorter total
times in TUGT test (−3.2%; Figure 5A); (b) an improvement in
10m walking performance, time needed to cover 10m (speed)
and number of steps during SPWT decreased (−5.1 and −4.2%,
respectively; Figure 5B); (c) higher score obtained in the SPPB
(6 vs. 8 points; Figure 5C). Taken together, these data suggest a
slight improvement of the patient’s ADL at T3. The reason for the
partially negative outcome at T1 and T2 will be further discussed
below (see section Discussion).
Histological and EM Analyses of FES
Treatment on Thigh Muscles
Muscle biopsies of Vastus Lateralis (VL) muscle were analyzed
by EM (Figure 6) and by histology for quantitative analysis
(Figures 6, 7; an image in cross section at lower magnification
is provided in Figure S1) before (T0) and after 14 months of FES
training (T2).
At the EM analysis (Figure 6) fibers presented with different
appearances: (a) apparently normal fibers, which displayed a
normal cross striation pattern of the skeletal muscle fibers
(Figure 6A); (b) fibers with unstructured cores (Figure 6B),
extended areas in which myofibrils were disrupted and
replaced by amorphous cytoplasmic material; and (c) fibers
with contracture cores (Figure 6C), regions with laterally-
packed and/or over-contracted myofibrils. In unstructured
cores, mitochondria were often damaged (Figure 6B),
while in contracture cores both mitochondria and SR were
scarce or completely missing (Figure 6C). Figure 7 shows
two representative histological images from biopsies before
(Figure 7A) and after the 14 months of FES training (Figure 7B):
we used this approach to evaluate whether FES improved fiber
structure and/or reduced the number of cores. Before FES
training (T0), only 18% of skeletal fibers analyzed displayed
the normal cross striation pattern, with the remaining 82%
presenting structural abnormalities, i.e., either unstructured or
contracture cores (see Figure 6). Following FES training, while
recovery was definitely not complete, the percentage of fibers
containing cores was significantly reduced from 82 to 53%
(Figure 6, columns B and C), accompanied by a parallel increase
(from 18 to 47%) in the percentage of fibers with a fairly normal
appearance (Figure 6, column A).
DISCUSSION
Background
CCD is a disorder usually associated with a mild to moderate
degree of disability. Weakness is usually slowly progressive, but
orthopedic complications often limit the ability of CCD adult
patients to perform physical exercise (2). While the use of anti-
oxidants is being considered for the treatment of patients (17,
18, 20), CCD has currently no cure, and the development of
strategies aiming to maintain muscle mass and strength could
be of help. FES has been previously used to rescue or maintain
muscle functions in individuals with no, or limited, capability to
perform physical exercise: FES was indeed beneficial to improve
muscle function in patients with spinal cord injury (27–29) and
in elderly individuals (30).
Main Findings of the Study
Here we tested the possibility of using FES to improve muscle
function in a 55-year-old female patient diagnosed with CCD
at the age of 44 by providing stimulators and electrodes to the
patient at home (see Figure S2). Sequence analysis of the RYR1
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gene in the patient identified a missense mutation (c.7354C>T)
in exon 46, which had been previously reported in an individual
with MHS (43) and a duplication (c.12853_12864dup12) in exon
91 (Figure 1). This duplication has not been reported in the
literature, but occurs in a region of the RYR1 gene where other
duplications associated with MHS have been reported (44, 45).
Actually, the duplication reported here partly overlaps with the
one we report in Levano et al. (45). The patients inherited
the c.12853_12864dup12 from the father, while the c.7354C>T
mutations was inherited from the mother. Absence of clinical
evidence ofmyopathy in the familymembers carrying only one of
the two mutation in the RYR1 gene and evidence of central core
in the proband carrying two mutations agrees with a recessive
form of CCD (19, 20, 46, 47).
The results of tests and experiments aiming to evaluate the
effects of FES on muscle function and structure were reasonably
encouraging. According to MRI analysis, FES treatment resulted
in a selective increase inmuscle mass (at T2 and T3) in stimulated
quadriceps (Figure 3), while no improvement was exerted on
the hamstring due to an unfavorable position of the electrodes
used to stimulate tight muscles. A reduction in fat mass area was
observed at T3. In addition, functional tests reported in Figure 4
also led to some positive outcomes:
(a) Maximum isometric force (MIF) of leg extensors improved
in both legs, already significantly at the fifth month of
stimulation (8% at T1), and continued to increase steadily
until the end of the treatment to achieve an improvement
of 11% at 26 months (T3) (Figure 4). The increase in force
may result from the combined effect of an increase in muscle
mass (Figure 3; discussed above) and of the improvement in
ultrastructure of skeletal fibers (Figures 6, 7). The qualitative
analysis was supported also by quantitative data revealing
a significant decrease in the percentage of fibers presenting
structural cores from T0 to T2: 82 vs. 53% (Figure 6).
(b) Stabilometric test (ST) also showed an improvement in
balance of the patient in both eyes-open and eyes-closed
conditions (Figure 4). Worth to notice also that already at
T1 (5 months) FES induced improvement in the ST test.
These results suggest that the subject’s balance may depend
on muscle mass and strength (Figures 3, 4), as previously
suggested (48, 49). The comparison of results in eyes-open
and eyes-closed conditions (a) indicates that muscle force
(likely needed to maintain balance) has a relatively greater
role in eyes-closed condition, (i.e., the condition without
visual perceptual information) and (b) suggests that the
strength of lower limbs is crucial for the transfer of balance
control skills to all environmental situations (50).
The results of the battery of ADL tests were less straightforward
than the ones collected with other approaches, as at T1 and T2
there were no evidence of improvement, but rather a general
worsening of performance in the various tasks, while at T3 scores
were improved compared to T0 (Figure 5). The reason for this
partial negative outcome is unclear. However, one of the possible
explanations is the low back-pain lamented by the patient for
several months during the trial, a problem that had temporally
caused a significant reduction in her daily walking activities.
However, it is important to underline that despite the low back
pain, at the end of the FES treatment (T3) all ADL tests showed
a slight improvement in the patient’s performance. The result of
ADL tests (Figure 5) are considered in literature as a parameter
to score the degree of independence (27, 51, 52) and an indirect
index of muscle strength (52).
CONCLUSIONS
The case report presented in this study represents an attempt
to find possible strategies for CCD patients to exercise muscles
in the lower extremities. Our results confirmed previous
finding on the effectiveness of the FES treatment in increasing
muscle strength in pathological subjects (27). The treatment
proved to have a strong compliance by the patient, which
make it to be a favorite choice for long-term home care
treatments. Results of this study are moderately encouraging
and suggest that FES could be considered as an additional
supportive measure to maintain/improve muscle function in
CCD patients.
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